Sinphar PharmaceuticalLtd (1734) Stock Overview
Engages in the production, processing, selling, and trading of various medicines, chinese medicines, medical cosmetic products and nutrients in Taiwan, Mainland China, Vietnam, Indonesia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
1734 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Sinphar Pharmaceutical Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$31.50 |
| 52 Week High | NT$32.60 |
| 52 Week Low | NT$29.62 |
| Beta | 0.12 |
| 1 Month Change | 1.94% |
| 3 Month Change | 2.27% |
| 1 Year Change | 1.46% |
| 3 Year Change | -1.73% |
| 5 Year Change | 15.42% |
| Change since IPO | 167.01% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1734 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | 2.6% | 1.3% | 4.4% |
| 1Y | 1.5% | -11.3% | 109.5% |
Return vs Industry: 1734 exceeded the TW Pharmaceuticals industry which returned -11.3% over the past year.
Return vs Market: 1734 underperformed the TW Market which returned 109.5% over the past year.
Price Volatility
| 1734 volatility | |
|---|---|
| 1734 Average Weekly Movement | 1.9% |
| Pharmaceuticals Industry Average Movement | 5.1% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in TW Market | 12.1% |
| 10% least volatile stocks in TW Market | 2.6% |
Stable Share Price: 1734 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 1734's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1977 | n/a | Youyang Bai | www.sinphar.com.tw |
Sinphar Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the production, processing, selling, and trading of various medicines, chinese medicines, medical cosmetic products and nutrients in Taiwan, Mainland China, Vietnam, Indonesia, and internationally. It operates through three segments: Pharmaceuticals, Healthy Food, and Others. The company offers pharmaceutical products, including antineoplastic, ophthalmic, ENT, oral, respiratory system, dermatology, analgesic and NSAIDs, metabolic and nutrient, gastrointestinal, and other products; and healthy food under the Sinphar, DailyCare, Migus, YouBest, and SynCoreBio brands.
Sinphar Pharmaceutical Co.,Ltd. Fundamentals Summary
| 1734 fundamental statistics | |
|---|---|
| Market cap | NT$5.96b |
| Earnings (TTM) | NT$327.17m |
| Revenue (TTM) | NT$3.39b |
Is 1734 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1734 income statement (TTM) | |
|---|---|
| Revenue | NT$3.39b |
| Cost of Revenue | NT$1.92b |
| Gross Profit | NT$1.48b |
| Other Expenses | NT$1.15b |
| Earnings | NT$327.17m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.72 |
| Gross Margin | 43.52% |
| Net Profit Margin | 9.64% |
| Debt/Equity Ratio | 43.4% |
How did 1734 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/05 08:29 |
| End of Day Share Price | 2026/06/05 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sinphar Pharmaceutical Co.,Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jianzheng Wu | Capital Securities Corporation |
| Hsiu Chi Lin | Masterlink Securities Investment Advisory |